Skip to main content

Press Releases and Ad-hoc Announcements

01 October 2024	PR: Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient	PDF
01 October 2024	AH: Heidelberg Pharma AG Announces Updated Guidance	PDF
23 September 2024	PR: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024	PDF
29 November 2023	PR: Heidelberg Pharma Announces Changes to the Executive Management Board	PDF
29 November 2023	AH: Heidelberg Pharma Announces Changes to the Executive Management Board	PDF
15 November 2023	PR: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform	PDF
02 November 2023	PR: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023	PDF
12 October 2023	PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023	PDF
19 September 2023	PR: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101	PDF
08 August 2023	PR: Heidelberg Pharma’s Partner Takeda Reached Development Milestone	PDF
13 July 2023	PR: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business	PDF
29 June 2023	AH: Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics	PDF
25 May 2023	PR: Heidelberg Pharma reports on the results of the Annual General Meeting 2023	PDF
05 May 2023	PR: Heidelberg Pharma appoints Chief Financial Officer	PDF
13 April 2023	PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023	PDF
04 April 2023	PR: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023	PDF
24 March 2023	PR: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business	PDF